• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CG Oncology (CGON) In Focus Following Early Trial Results And BLA Timing Questions On Value

    Simply Wall St·07/13/2026 22:24:15
    語音播報

    Early trial results and BLA timeline put CG Oncology in focus

    CG Oncology (CGON) is back in the spotlight after positive early Phase II data for cretostimogene grenadenorepvec with gemcitabine and clearer timing for a planned biologics license application in high-risk bladder cancer.

    See our latest analysis for CG Oncology.

    The recent early Phase II update and clearer BLA timeline appear to be feeding into sentiment around CG Oncology, with a 30-day share price return of 21.73% and a year to date share price return of 73.49%, while the 1-year total shareholder return of 179.92% points to strong momentum over a longer stretch despite a 1-day share price decline of 3.64%.

    If CG Oncology's clinical progress has caught your attention, this could be a good moment to broaden your watchlist with other potential healthcare AI growth stories using the 40 healthcare AI stocks.

    CG Oncology’s lead bladder cancer program and strong recent share price momentum are one side of the story; the other is whether the current US$72.50 share price still reflects a reasonable entry point for new capital.

    Preferred Price to Book Multiple of 5.9x: Is It Justified?

    With CG Oncology trading at $72.50, the stock is described as good value against its estimated fair value, yet its current price tag comes with a P/B ratio of 5.9x that investors will want to unpack.

    The P/B ratio compares a company’s market value to the book value of its net assets. This can be a useful yardstick for early stage biopharma stocks that are still loss making. In CG Oncology’s case, the stock is flagged as good value based on its P/B of 5.9x versus a peer group average of 25.2x. This suggests the market is assigning a lower multiple to its balance sheet than some similar companies.

    At the same time, the stock is described as expensive relative to the broader US Biotechs industry, where the average P/B sits at 2.7x. That mix of being cheaper than a selected peer set but richer than the wider industry, combined with an internal DCF view that puts fair value at $427.70 per share and an analyst price target of $90.29, highlights how sensitive CG Oncology’s valuation is to expectations for future cash flows and eventual profitability.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 5.9x (UNDERVALUED)

    However, CG Oncology still faces risks around ongoing clinical trials and the company’s current loss of US$186.75m, which could pressure funding needs and investor confidence.

    Find out about the key risks to this CG Oncology narrative.

    Another View: SWS DCF model points to a very different valuation

    While CG Oncology’s 5.9x P/B ratio suggests the stock is cheaper than some peers, the SWS DCF model presents a very different picture. With an estimated future cash flow value of $427.70 per share versus today’s $72.50 price, the model indicates the stock may be significantly undervalued. The question for you is whether those cash flow assumptions appear realistic for a still unprofitable biotech.

    Look into how the SWS DCF model arrives at its fair value.

    CGON Discounted Cash Flow as at Jul 2026
    CGON Discounted Cash Flow as at Jul 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Given the mix of optimism and caution around CG Oncology, it makes sense to look at the same numbers yourself and decide where you stand. If you want a structured view of both sides of the story, take a closer look at the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond CG Oncology?

    If CG Oncology has sharpened your focus on potential opportunities, do not stop here. Use the Simply Wall Street Screener to uncover more ideas aligned with your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.